全文获取类型
收费全文 | 30094篇 |
免费 | 2351篇 |
国内免费 | 187篇 |
专业分类
耳鼻咽喉 | 464篇 |
儿科学 | 932篇 |
妇产科学 | 560篇 |
基础医学 | 3287篇 |
口腔科学 | 652篇 |
临床医学 | 3027篇 |
内科学 | 6052篇 |
皮肤病学 | 662篇 |
神经病学 | 1678篇 |
特种医学 | 1297篇 |
外国民族医学 | 7篇 |
外科学 | 4966篇 |
综合类 | 1074篇 |
一般理论 | 16篇 |
预防医学 | 1702篇 |
眼科学 | 962篇 |
药学 | 2608篇 |
15篇 | |
中国医学 | 279篇 |
肿瘤学 | 2392篇 |
出版年
2023年 | 313篇 |
2022年 | 553篇 |
2021年 | 1450篇 |
2020年 | 815篇 |
2019年 | 1068篇 |
2018年 | 1202篇 |
2017年 | 872篇 |
2016年 | 851篇 |
2015年 | 1025篇 |
2014年 | 1431篇 |
2013年 | 1588篇 |
2012年 | 2306篇 |
2011年 | 2300篇 |
2010年 | 1193篇 |
2009年 | 1093篇 |
2008年 | 1665篇 |
2007年 | 1567篇 |
2006年 | 1405篇 |
2005年 | 1226篇 |
2004年 | 1077篇 |
2003年 | 931篇 |
2002年 | 779篇 |
2001年 | 645篇 |
2000年 | 600篇 |
1999年 | 539篇 |
1998年 | 195篇 |
1997年 | 169篇 |
1996年 | 153篇 |
1995年 | 155篇 |
1994年 | 132篇 |
1993年 | 112篇 |
1992年 | 281篇 |
1991年 | 292篇 |
1990年 | 255篇 |
1989年 | 222篇 |
1988年 | 212篇 |
1987年 | 223篇 |
1986年 | 194篇 |
1985年 | 179篇 |
1984年 | 113篇 |
1983年 | 128篇 |
1982年 | 87篇 |
1981年 | 72篇 |
1980年 | 61篇 |
1979年 | 131篇 |
1978年 | 77篇 |
1977年 | 69篇 |
1974年 | 65篇 |
1973年 | 90篇 |
1970年 | 58篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
931.
932.
933.
Marchaim D Chopra T Bogan C Bheemreddy S Sengstock D Jagarlamudi R Malani A Lemanek L Moshos J Lephart PR Ku K Hasan A Lee J Khandker N Blunden C Geffert SF Moody M Hiro R Wang Y Ahmad F Mohammadi T Faruque O Patel D Pogue JM Hayakawa K Dhar S Kaye KS 《American journal of infection control》2012,40(8):760-765
934.
Moody J Cosgrove SE Olmsted R Septimus E Aureden K Oriola S Patel GW Trivedi KK 《American journal of infection control》2012,40(2):94-95
It is clear that the widespread and injudicious use of antimicrobials has greatly increased the presence of MDROs that threaten the health of all. There is worldwide acknowledgement that this threat is growing, and that prudent use of antimicrobials combined with infection prevention can prevent harm and improve patient safety. Antimicrobial stewardship programs must harness the talents of all members of the health care team to effectively identify the organism, determine its susceptibility, institute any precautions required, and prescribe the narrowest-acting antibiotic that will destroy it. IPs/HEs play a pivotal role in this approach, by assisting with early organism and infected patient identification, by promoting compliance with standard and transmission-based precautions and other infection prevention strategies such as care bundle practices, hand hygiene, and by educating staff, patients, and visitors. 相似文献
935.
Naggie S Osinusi A Katsounas A Lempicki R Herrmann E Thompson AJ Clark PJ Patel K Muir AJ McHutchison JG Schlaak JF Trippler M Shivakumar B Masur H Polis MA Kottilil S 《Hepatology (Baltimore, Md.)》2012,56(2):444-454
Recent studies have shown that a single-nucleotide polymorphism upstream of the interleukin-28B (IL28B) gene plays a major role in predicting therapeutic response in hepatitis C virus (HCV)-infected patients treated with pegylated interferon (PEG-IFN)/ribavirin. We sought to investigate the mechanism of the IL28B polymorphism, specifically as it relates to early HCV viral kinetics, IFN pharmacokinetics, IFN pharmacodynamics, and gene expression profiles. Two prospective cohorts (human immunodeficiency virus [HIV]/HCV-coinfected and HCV-monoinfected) completing treatment with IFN/ribavirin were enrolled. Patients were genotyped at the polymorphic site rs12979860. In the HIV/HCV cohort, frequent serum sampling was completed for HCV RNA and IFN levels. DNA microarray of peripheral blood mononuclear cells and individual expression of IFN-stimulated genes (ISGs) were quantified on IFN therapy. The IL28B-favorable (CC) genotype was associated with improved therapeutic response compared with unfavorable (CT or TT) genotypes. Patients with a favorable genotype had greater first- and second-phase viral kinetics (P = 0.004 and P = 0.036, respectively), IFN maximum antiviral efficiency (P = 0.007) and infected cell death loss (P = 0.009) compared with unfavorable genotypes. Functional annotation analysis of DNA microarray data was consistent with depressed innate immune function, particularly of natural killer cells, from patients with unfavorable genotypes (P <0.004). Induction of innate immunity genes was also lower in unfavorable genotypes. ISG expression at baseline and induction with IFN was independent of IL28B genotype. CONCLUSION: Carriers of the IL28B-favorable genotype were more likely to have superior innate immune response to IFN therapy compared with unfavorable genotypes, suggesting that the unfavorable genotype has aberrant baseline induction of innate immune response pathways resulting in impaired virologic response. IL28B genotype is associated with more rapid viral kinetics and improved treatment response outcomes independent of ISG expression. 相似文献
936.
937.
Clark PJ Thompson AJ Vock DM Kratz LE Tolun AA Muir AJ McHutchison JG Subramanian M Millington DM Kelley RI Patel K 《Hepatology (Baltimore, Md.)》2012,56(1):49-56
Hepatitis C virus (HCV) subverts host cholesterol metabolism for key processes in its lifecycle. How this interference results in the frequently observed, genotype-dependent clinical sequelae of hypocholesterolemia, hepatic steatosis, and insulin resistance (IR) remains incompletely understood. Hypocholesterolemia typically resolves after sustained viral response (SVR), implicating viral interference in host lipid metabolism. Using a targeted cholesterol metabolomic platform we evaluated paired HCV genotype 2 (G2) and G3 patient sera for changes in in vivo HCV sterol pathway metabolites. We compared HCV genotypic differences in baseline metabolites and following antiviral treatment to assess whether sterol perturbation resolved after HCV eradication. We linked these metabolites to IR and urine oxidative stress markers. In paired sera from HCV G2 (n = 13) and G3 (n = 20) patients, baseline sterol levels were lower in G3 than G2 for distal metabolites (7-dehyrocholesterol (7DHC) 0.017 versus 0.023 mg/dL; P(adj) = 0.0524, cholesterol 140.9 versus 178.7 mg/dL; P(adj) = 0.0242) but not the proximal metabolite lanosterol. In HCV G3, SVR resulted in increased levels of distal metabolites (cholesterol [Δ55.2 mg/dL; P(adj) = 0.0015], 7DHC [Δ0.0075 mg/dL; P(adj) = 0.0026], lathosterol [Δ0.0430 mg/dL P(adj) = 0.0405]). In contrast, lanosterol was unchanged after SVR (P = 0.9515). CONCLUSION: HCV G3, but not G2, selectively interferes with the late cholesterol synthesis pathway, evidenced by lower distal sterol metabolites and preserved lanosterol levels. This distal interference resolves with SVR. Normal lanosterol levels provide a signal for the continued proteolysis of 3-hydroxyl-3-methylglutaryl coenzyme A reductase, which may undermine other host responses to increase cholesterol synthesis. These data may provide a hypothesis to explain why hypocholesterolemia persists in chronic HCV infection, particularly in HCV G3, and is not overcome by host cholesterol compensatory mechanisms. 相似文献
938.
Lambrou GI Papadimitriou L Chrousos GP Vlahopoulos SA 《Molecular and cellular endocrinology》2012,351(2):142-151
Twenty years ago a proteasome inhibitor was suggested as therapy for glucocorticoid-resistant multiple myeloma, a disease that involves terminally differentiated B cells. Since then, research has proven that it has utility on a number of tumors resistant to chemotherapy. Hematologic malignancy, however, often involves lesser differentiated cells, which have a high potential to modulate their intrinsic machinery and thereby activate alternative rescue pathways. A corresponding multiplicity of therapies is not always practical. One approach to conditions with heterogeneous physiology is to identify key biochemical mediators, thereby reducing the number of treatment targets. Results from several ongoing studies indicate convergence of genomically diverse signal pathways to a limited number of key downstream regulators of apoptosis. Convergence of pathways can be exploited to address the problem of genetic heterogeneity in acute leukemia: this would mean treating multiple molecular aberrations with fewer drugs and enhanced therapeutic benefit. 相似文献
939.
The complexity of the human female reproductive tract (FRT) with its multiple levels of hormonally controlled immune protection has only begun to be understood. Dissecting the functions and roles of the immune system in the FRT is complicated by the differential hormonal regulation of its distinct anatomical structures that vary throughout the menstrual cycle. Although many fundamental mechanisms of steroid regulation of reproductive tract immune function have been determined, the effects of exogenous synthetic steroids or endocrine disruptors on immune function and disease susceptibility in the FRT have yet to be evaluated in detail. There is increasing evidence that environmental or synthetic molecules can alter normal immune function. This review provides an overview of the innate and adaptive immune systems, the current status of immune function in the FRT and the potential risks of environmental or pharmacological molecules that may perturb this system. 相似文献
940.